PRACTI PRACT CAL H
ITIO A ANGELOTEST
PharmacologyforAdvancedPracticeNursing(KennesawStateUniversity)
Studocu isnotsponsoredorendorsedbyanycollege oruniversity
V b V V
DownloadedbyPatrickLiquete()
b b
,Chapter1IssuesforthePractitionerinDrugTherapy
MULTIPLECHOICE
1. Nursepractitionerprescriptiveauthorityisregulatedby:
A. TheNationalCouncilofStateBoardsofNursing
B. TheU.S.DrugEnforcementAdministration b
C. TheStateBoard ofNursingforeachstate V
D. TheStateBoard ofPharmacy V
ANS: C b b PTS: 1
2. PhysicianAssistant(PA)prescriptiveauthorityisregulatedby:
A. TheNationalCouncilofStateBoardsofNursing
B. TheU.S.DrugEnforcementAdministration b
C. TheStateBoard ofNursing V
D. TheStateBoard ofMedicalExaminers V
ANS: D b b PTS: 1
3. Clinicaljudgment inprescribingincludes:
V V
A. Factoringinthecosttothepatientofthemedicationprescribed
B. Alwaysprescribingthenewestmedicationavailable forthediseaseprocess Vb V
C. Handingoutdrugsamplestopoorpatients
D. Prescribingallgenericmedicationstocutcosts
V
ANS: A b b PTS: 1
4. Criteriaforchoosing an effectivedrug for adisorderinclude:
V V b b V b b V b b
A. Askingthepatient whatdrugtheythinkwouldwork bestforthem
V V V
B. Consultingnationallyrecognizedguidelinesfordiseasemanagement
V
C. Prescribingmedicationsthat areavailableassamplesbeforewritingaprescription
V V V
D. FollowingU.S.DrugEnforcementAdministration(DEA)guidelinesfor V
prescribing
b
ANS: B b b PTS: 1
5. Nursepractitionerpracticemaythriveunderhealth-carereform dueto: V
A. Thedemonstratedabilityofnursepractitionerstocontrolcostsandimprovepatient V
outcomes
b
B. Thefactthatnursepractitionerswillbeabletopracticeindependently
C. Thefactthatnursepractitionerswillhavefullreimbursementunderhealth-care
V V V V
reform
b
D. Theabilitytoshift accountabilityforMedicaid tothestatelevel
V V
ANS: A b b PTS: 1
DownloadedbyPatrickLiquete()
b b
,Chapter2.PharmacokineticBasisofTherapeuticsandPharmacodynamic
MULTIPLECHOICE
1. Apatient'snutritionalintakeandlabworkreflectshypoalbuminemia.Thisiscriticalto b
b prescribingbecause:
A. Distributionofdrugstotargettissuemaybeaffected
B. Thesolubilityofthedrugwillnotmatchthesiteofabsorption V
C. Therewillbelessfreedrug availabletogenerateaneffect Vb
D. Drugsboundtoalbumin arereadilyexcretedbythekidney V V
ANS: A b b PTS: 1
2. Drugsthathaveasignificantfirst-passeffect:
V
A. Mustbegivenbytheenteral(oral) routeonly
V b
B. Bypassthehepaticcirculation
C. Arerapidlymetabolizedbytheliverandmayhavelittleifanydesiredaction
D. Areconvertedbythelivertomoreactiveandfat-solubleforms
ANS: C b b PTS: 1
3. Therouteofexcretionofavolatiledrugwilllikelybe:
A. Thekidneys
B. Thelungs
C. Thebileand feces Vb
D. Theskin
ANS: B b b PTS: 1
4. Medroxyprogesterone(DepoProvera)isprescribedIMtocreateastoragereservoirofthedrug. V V b
Storagereservoirs:
b
A. Assurethatthe drug will reachitsintended targettissue
V V V V
B. Arethereason forgivingloadingdoses V V
C. Increasethelength oftimea drugis availableandactive
V V V V
D. Aremostcommon incollagentissues V
ANS: C b b PTS: 1
5. TheNPchoosestogivecephalexinevery8hoursbasedonknowledgeofthedrug's: V
A. Propensitytogotothetargetreceptor b
B. Biological half-life V
C. Pharmacodynamics
D. Safetyand sideeffectsV
ANS: B b b PTS: 1
6. Azithromycindosingrequiresthefirst day's dosebetwicethoseoftheother4daysofthe V V V b
b prescription.Thisisconsideredaloadingdose.Aloadingdose:
A. Rapidlyachievesdruglevelsin thetherapeuticrange V V
B. Requiresfourtofivehalf-livestoattain V
C. Isinfluencedbyrenal function b
DownloadedbyPatrickLiquete()
b b
, D. Isdirectlyrelated tothedrugcirculatingtothetarget tissues
V V V
ANS: Ab b PTS: 1
7. Thepointintimeonthedrugconcentrationcurvethatindicatesthefirstsignofatherapeuticeffectis
V V b
bthe:
A. Minimumadverseeffect level V
B. Peakofaction
C. Onsetofaction
D. Therapeuticrange
ANS: Cb b PTS: 1
8. Phenytoinrequires atroughlevelbedrawn.Peak andtroughlevelsaredone:
V V
A. Whenthedrughasawidetherapeuticrange
V
B. When thedrugwillbeadministered forashorttimeonly
V V
C. Whenthereisahighcorrelationbetweenthedoseandsaturationofreceptorsites
V
D. Todetermineifa drugisinthetherapeuticrange
V V
ANS: Db b PTS: 1
9. Alaboratoryresultindicatesthepeaklevelforadrugisabovetheminimumtoxic
V V V
bconcentration.Thismeans that the: V V
A. Concentrationwillproducetherapeuticeffects
V
B. Concentrationwillproduceanadverseresponse
C. Timebetweendosesmust beshortened V
D. Durationofaction ofthedrugistoolong V
ANS: Bb b PTS: 1
10. Drugsthatarereceptoragonistsmaydemonstratewhatproperty?
V V
A. Irreversiblebindingtothedrugreceptorsite V
B. Up-regulationwithchronic use V
C. Desensitizationordown-regulationwithcontinuoususe V
D. Inverserelationshipbetween drug concentrationanddrugaction V V
ANS: Cb b PTS: 1
11. Drugsthatarereceptorantagonists,suchasbetablockers,maycause:
V V
A. Down-regulationofthedrugreceptor
B. Anexaggeratedresponseifabruptlydiscontinued
V
C. Partialblockadeoftheeffectsofagonistdrugs
D. An exaggeratedresponsetocompetitivedrug agonists
V V
ANS: Bb b PTS: 1
12. Factorsthataffectgastricdrugabsorptioninclude:
A. Liverenzymeactivity
B. Protein-bindingpropertiesofthedrugmolecule
C. Lipidsolubilityofthedrug
V
D. Abilitytochewandswallow
ANS: Cb b PTS: 1
DownloadedbyPatrickLiquete()
b b